🌟 A big thank you to everyone who visited us at #CPHIChina2025 🌟 It was fantastic connecting with industry leaders and showcasing our insulin products and innovative delivery devices. Your interest, insights, and collaborative spirit made this event an incredible success. 🤝 READ MORE: https://lnkd.in/gseUewpZ #GanLee #CPHIChina #CPHI2025
关于我们
甘李药业成立于1998年，致力于科研、开发、生产和销售用于治疗糖尿病、肿瘤、自身免疫等重大疾病的创新药物。2020年6月29日，甘李药业在上海证券交易所主板挂牌上市，股票代码：603087。 甘李药业总部位于北京，是中国第一家掌握产业化生产重组胰岛素类似物技术的高科技生物制药企业，具备完整胰岛素研发管线。目前，公司已拥有长效甘精胰岛素注射液（长秀霖®）、速效赖脯胰岛素注射液（速秀霖®）、精蛋白锌重组赖脯胰岛素混合注射液（25R）（速秀霖®25）、门冬胰岛素注射液（锐秀霖®）及门冬胰岛素30注射液（锐秀霖®30）五个重组胰岛素类似物品种，产品覆盖长效、速效、中效三个胰岛素功能细分市场，以及拥有配套的胰岛素注射笔及针头产品。 自2005年以来，公司凭借良好的产品质量和先进的生产技术优势，陆续在全球四十多个国家和地区建立了国际化商业网络，海外市场实现了迅速扩张。同时，甘李药业的甘精、赖脯和门冬三款胰岛素产品在欧美的临床试验也进入收尾阶段，意味着公司的产品即将在欧美等发达国家获批上市。 在未来，甘李药业将实现在糖尿病诊断和治疗领域产品线全面覆盖，进一步提升公司在糖尿病治疗领域的市场竞争力。同时还将积极投入到肿瘤、自身免疫等多个研究领域，提供多样化、高质量的医药产品及服务，造福全球更多患者，为成为世界一流的医药公司而不断前行。
- 网站
-
http://www.ganlee.com/en
甘李药业股份有限公司 | Gan & Lee的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Tongzhou District，Beijing
- 类型
- 上市公司
- 创立
- 1998
- 领域
- Diabetes、Insulin、Biosimilars和Medical Device
地点
-
主要
获取路线
No.8 Nanfeng West 1st Street, Huoxian
CN，Beijing，Tongzhou District，101109
甘李药业股份有限公司 | Gan & Lee员工
-
Shaun King
-
Spencer Carter
Senior Leader, Business Development, Life Sciences R&D and Strategic Innovation | Linking Leadership, BD, Ops, Regulatory, and Technical Innovation…
-
Maria Diaz Genovese
Associate Director, Global Program Management
-
Elena A Christofides, MD, FACE
Physician l Scientist l Research l Author l Medical l Bio-Tech Business Accelerator l Award Winning Educator
动态
-
The American Diabetes Association's 85th Scientific Sessions have concluded, but the learning and collaboration continue. We’re grateful for the overwhelming support, particularly from those who engaged with us at our booth and during our oral presentation. Let’s work together to shape the future of diabetes care. Learn more: https://lnkd.in/gQ9cs8Pq. 🌟 #ADASciSessions #GanLee #DiabetesCare #Partnerships
-
Day 2 of the 85th ADA Scientific Sessions is underway! We’re at 📍Booth 2614, ready to discuss how we’re advancing diabetes care.🎉 Stop by, say hello, and see what’s new. Let’s make this a productive meeting! #GanLee #ADASciSessions #DiabetesCare #OpeningDay #Booth2614
-
-
Exciting news from Gan & Lee! 🌟 We’re thrilled to share promising advancements in diabetes and obesity treatments unveiled at the American Diabetes Association’s 85th Scientific Sessions. Stay tuned for more updates as we continue to pioneer innovation in healthcare. Learn more: https://lnkd.in/gsZCriZb #GanLee 🔬 #ADASciSessions #ADA2025
-
🌟 Don’t miss Gan & Lee at the American Diabetes Association 85th Scientific Sessions !🌟 📍 Booth: 2614 🗓️ Dates: June 21-23, 2025 📍 Location: [McCormick Place, Chicago, IL] Visit us to see our latest innovations and learn how we’re advancing diabetes care. See you there! #GanLee #ADASciSessions #DiabetesResearch #InnovationInCare #Booth2614
-
-
Gan & Lee’s Insulin Aspart Approved in Malaysia!🌏 Our fast-acting insulin aspart is now NPRA-approved — following insulin glargine and aspart 30 earlier this year. And First time we’ve achieved full insulin portfolio approval (basal + fast-acting + premix) in a PIC/S member country. Proud to expand access to quality insulin options in Malaysia. Read More: https://lnkd.in/g86eP3CN #GanLee #NPRA #DiabetesCare #GlobalHealth
-
🌍 Following the International Diabetes Academic Conference 2025, over 50 global KOLs visited Gan & Lee Pharmaceuticals' HQ in Beijing. As the first Chinese insulin company with EU GMP certification, we’re proud to share our intelligent manufacturing, rigorous quality systems, and international vision with the world. Read More: https://lnkd.in/ghc4AiKx #GanLee #Diabetes #GlobalHealth
-
We're thrilled to partner with Biomm and Fiocruz in advancing Brazil's healthcare autonomy! This collaboration marks a significant step in localizing high-quality insulin production. Gan & Lee is proud to contribute our expertise in biosimilars to support Brazil's mission of reducing import dependency and verticalizing insulin manufacturing. Our shared commitment to innovation will ensure sustainable access to life-saving therapies like insulin glargine for Brazilian patients. We look forward to driving more breakthroughs through this strategic alliance. Great insights by CEO Heraldo Marchezini on the transformative power of PDP. Watch the full interview here: https://lnkd.in/dv-Fyz_i
O CEO da Biomm, Heraldo M., revela em entrevista para a TIMES BRASIL - LICENCIADO EXCLUSIVO CNBC, como a nova parceria com a Gan & Lee Pharmaceuticals e a Fiocruz ampliará a produção nacional de insulina glargina, reduzirá nossa dependência de importações e contribuirá para verticalização da produção de insulina no Brasil. Destacou também a importância das PDPs para o sistema de saúde brasileiro. Com uma fábrica de R$ 800 milhões em Minas Gerais e planos de produzir 20 milhões de unidades de insulinas por ano, o Brasil dá um passo gigante rumo à autonomia em saúde. O CEO enfatizou outras parcerias com empresas internacionais consolidadas, o recente lançamento do Bevacizumabe da Biomm, um anticorpo monoclonal voltado ao tratamento de vários tipos de câncer, e em breve o lançamento do Ranibizumabe, produto indicado para tratar diferentes doenças da retina. Acesse o link para assistir a entrevista na íntegra e conhecer os resultados da Biomm no primeiro trimestre e a projeção de resultados para 2025, assista em: https://lnkd.in/dv-Fyz_i #InsulinaNacional #Biomm #SUS #SaúdePública #ParceriaEstratégica #acesso #pdp #oncologia #oftalmologia
-
-
🌍 The Multinational Diabetes Academic Conference 2025 has successfully concluded in Beijing. Hosted by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) with support from Gan & Lee Pharmaceuticals, the scientific gathered diabetes experts from 7 countries to explore the latest progress in diabetes prevention and treatment. The scientific program focused on four pivotal thematic areas: "Diabetes Epidemiology" "GLP-1 RA " "The Progress of Diabetes Prevention and Treatment" and "Innovative Patient Management". Learn more:https://lnkd.in/gbvMA55g #GanLee #DiabetesCare #GlobalHealth